Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti- PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: A camera controller (1) with an image data stream input (2) and an image data stream output (4), wherein a first image data stream path (3) and a second image data stream path (5) are formed. An image processing unit (6) is arranged in the second image data stream path (5). A switching unit (7) is controlled by a comparison unit (8). The comparison unit (8) compares a first checking data stream (9), which was diverted from an image data stream (1) upstream of the image processing unit (6), and a second checking data stream (10), which was diverted from the image data stream downstream of the image processing unit (6). The image data stream paths are switched via the switching unit (7) if the deviation of the second checking data stream (9) from the first checking data stream (10) exceeds a threshold value.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: Oil ash comprising carbon in an amount in the range of 60% to 89% is an effective set retarder in a cement composition. The oil ash prolonged the initial and final setting time of cement paste and retained the slump flow in concrete for a longer time than concrete without the retarder. Also, the addition of oil ash to cement marginally improved the compressive strength of concrete. The advantage of oil ash is that it can be used as a solid retarder of cement hydration to substitute for the conventional commercial retarding admixtures with a limited shelf-life.

Abstract: Disclosed are methods comprising determining experimental data associated with one or more monoclonal antibodies (mAbs), determining computationally-derived data associated with the one or more mAbs, wherein the computationally-derived data comprises one or more computational parameters weighted based on accessible surfaces (ASAs) of one or more residues of the one or more mAbs, determining, based on the experimental data and the computationally-derived data, a plurality of candidate predictive models, determining an optimal predictive model from the plurality of candidate predictive models, and outputting the optimal predictive model.

Abstract: Concrete compositions containing cement, a fine aggregate such as sand, a coarse aggregate such as crushed limestone, an industrial waste material such as electric arc furnace dust, cement kiln dust, oil ash, or limestone powder. High performance concretes made therefrom and methods of producing such concretes are also specified. The addition of industrial waste materials and nano silica provides enhanced mechanical strength (e.g. compressive strength, flexural strength) and improved durability (e.g. resistance to penetration of chloride ions) to the high performance concretes.

Abstract: A camera controller (1) with an image data stream input (2) and an image data stream output (4), wherein a first image data stream path (3) and a second image data stream path (5) are formed. An image processing unit (6) is arranged in the second image data stream path (5). A switching unit (7) is controlled by a comparison unit (8). The comparison unit (8) compares a first checking data stream (9), which was diverted from an image data stream (1) upstream of the image processing unit (6), and a second checking data stream (10), which was diverted from the image data stream downstream of the image processing unit (6). The image data stream paths are switched via the switching unit (7) if the deviation of the second checking data stream (9) from the first checking data stream (10) exceeds a threshold value.

Abstract: Oil ash comprising carbon in an amount in the range of 60% to 89% is an effective set retarder in a cement composition. The oil ash prolonged the initial and final setting time of cement paste and retained the slump flow in concrete for a longer time than concrete without the retarder. Also, the addition of oil ash to cement marginally improved the compressive strength of concrete. The advantage of oil ash is that it can be used as a solid retarder of cement hydration to substitute for the conventional commercial retarding admixtures with a limited shelf-life.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: Concrete compositions containing cement, a fine aggregate such as sand, a coarse aggregate such as crushed limestone, an industrial waste material such as electric arc furnace dust, cement kiln dust, oil ash, or limestone powder. High performance concretes made therefrom and methods of producing such concretes are also specified. The addition of industrial waste materials and nano silica provides enhanced mechanical strength (e.g. compressive strength, flexural strength) and improved durability (e.g. resistance to penetration of chloride ions) to the high performance concretes.

Abstract: A calcium aluminate cement protective coating is resistant to sulfuric acid and can be used as a lining to protect surfaces in sulfur storage vessels and sulfuric acid storage vessels. The protective coating can include calcium aluminate cement, calcium aluminate based synthetic aggregates, and water. The protective coating is resistant to sulfur and sulfuric acid attack, and thus can be used to protect surfaces inside sulfur storage pits, sulfur storage tanks, and sulfuric acid storage containers.

Abstract: The present invention provides formulations of anti-IL-10 hum12G8, and their use in treating various disorders.

Abstract: A foam concrete has constituents that include a cement, a sand, a coarse aggregate having a density in a range of 1400-1600 kg/m3, a water, and a foam solution. The foam solution includes a foaming agent and a foaming water. The foam concrete has a compressive strength of at least 20 MPa, a thermal conductivity of less than 0.40 W/mK and a maximum dry weight of 2000 kg/m3.

Abstract: A foam concrete with elemental sulfur has constituents that include a cement, a fine filler, an elemental sulfur in powder form, a coarse aggregate, a water, and a foam solution. The foam solution includes a foaming agent and a foaming water. The foam concrete has a compressive strength of at least 26 MPa, a thermal conductivity of less than 0.30 W/mK and a maximum dry weight of 1620 kg/m3.

Abstract: The present invention provides abuse-resistant transdermal delivery devices containing an opioid agonist intended for analgesic purposes in pain patients.

Abstract: This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced blood flow to a tissue in a patient.

Abstract: This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced blood flow to a tissue in a patient.

Abstract: This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced blood flow to a tissue in a patient.

Abstract: A calcium alumninate cement protective coating is resistant to sulfuric acid and can be used as a lining to protect surfaces in sulfur storage vessels and sulfuric acid storage vessels. The protective coating can include calcium aluminate cement, calcium aluminate based synthetic aggregates, and water. The protective coating is resistant to sulfur and sulfuric acid attack, and thus can be used to protect surfaces inside sulfur storage pits, sulfur storage tanks, and sulfuric acid storage containers.